Technical Analysis for SGIOF - Shionogi & Co Ltd

Grade Last Price % Change Price Change
grade C 58.21 -3.50% -2.1100
SGIOF closed down 3.5 percent on Monday, August 3, 2020, on 35 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical SGIOF trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Hammer Candlestick Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Older signals for SGIOF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. Its primary products include Cymbalta, a serotonin and noradrenaline reuptake inhibitor used for the treatment of depression, anxiety, diabetic neuropathic pain, fibromyalgia pain, chronic lower back pain, and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist to treat attention-deficit hyperactivity disorder; Xofluza, an anti-influenza agent; and Symproic, a cancer pain analgesic tablet. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; strategic collaboration with Sage Therapeutics, Inc. to develop and commercialize SAGE-217 for MDD and other indications; license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics Inc.; a strategic collaboration with Tetra Discovery Partners LLC for the clinical development and commercialization of BPN14770, a selective phosphodiesterase-4D allosteric inhibitor; and a collaborative research agreement with PeptiDream Inc. for the discovery and development of a series of blood brain barrier penetrating peptide drug-conjugates. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Chemistry RTT Cancer Pharmaceuticals Drugs Pain Drug Discovery Infectious Diseases Chemical Compounds Osteoarthritis Depression Back Pain Fibromyalgia Attention Deficit Hyperactivity Disorder Psychiatric Disorders Treatment Of Depression Kyoto University Metabolic Syndrome Shionogi Depression Treatment Duloxetine Mycobacterial Diseases Naldemedine National University Corporation Kyoto University Symproic Treatment Of Mycobacterial Diseases Treatment Of Psychiatric Disorders

Is SGIOF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 70.32
52 Week Low 39.84
Average Volume 1,716
200-Day Moving Average 58.7854
50-Day Moving Average 60.0318
20-Day Moving Average 59.7280
10-Day Moving Average 60.1100
Average True Range 2.1141
ADX 14.13
+DI 19.3654
-DI 35.6385
Chandelier Exit (Long, 3 ATRs ) 58.6277
Chandelier Exit (Short, 3 ATRs ) 62.2023
Upper Bollinger Band 62.4209
Lower Bollinger Band 57.0351
Percent B (%b) 0.22
BandWidth 9.0172
MACD Line -0.0718
MACD Signal Line -0.0043
MACD Histogram -0.0675
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.9800
Resistance 3 (R3) 59.8400 59.1100 59.6850
Resistance 2 (R2) 59.1100 58.6592 59.1800 59.5866
Resistance 1 (R1) 58.6600 58.3808 58.2950 58.8000 59.4883
Pivot Point 57.9300 57.9300 57.7475 58.0000 57.9300
Support 1 (S1) 57.4800 57.4792 57.1150 57.6200 56.9317
Support 2 (S2) 56.7500 57.2008 56.8200 56.8334
Support 3 (S3) 56.3000 56.7500 56.7350
Support 4 (S4) 56.4400